
|Articles|March 1, 2002
Oritavancin shortens treatment time for complicated skin-structure infections
Chicago - Oritavancin (InterMune), an investigational glycopeptidewith activity against a wide range of Gram-positive pathogens, has beenshown to cut the treatment time in half for complicated skin and skin structureinfections (CSSIs) compared to current standard therapy with vancomycinplus cephalexin, Margaret Wasilewski, M.D., said at the 41st InterscienceConference on Antimicrobial Agents & Chemotherapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














